Online and face-to-face programmes to suit your CPD needs, apply now for September 2018
Page URL: https://www.bionews.org.uk/page_95484

AstraZeneca to launch its own 'two million genomes' project

25 April 2016
Appeared in BioNews 848

Pharmaceutical company AstraZeneca has signed deals with the Wellcome Trust Sanger Institute in the UK, the Institute for Molecular Medicine in Finland, and Dr Craig Venter's Human Longevity start-up, to launch one of the largest genome-sequencing efforts yet undertaken.

As part of the renewed personalised medicine push, AstraZeneca will establish its own Centre for Genomics Research, where scientists will draw on a database of genome sequences and clinical trial data. The company says that by investing heavily in genomics it aims to sharpen its target identification efforts, improve selection of participants for clinical trials, and allow patients to be matched with treatments more likely to benefit them.

Dr Menelas Pangalos, executive vice president at AstraZeneca, said: 'We will leverage information from up to two million genome sequences, including over 500,000 from our own clinical trials, to drive drug discovery and development across all our therapeutic areas.'

A ten-year partnership with Human Longevity, based in San Diego, California, is at the heart of AstraZeneca's programme. In addition to sequencing the 500,000 genomic samples from AstraZeneca clinical trials, Human Longevity will give AstraZeneca access to its database of genome sequences and health records, which the company says should contain one million entries by 2020.

Dr Venter, the founder and chief executive of Human Longevity, said his company would work with AstraZeneca 'and use Human Longevity's proprietary computational methods and genomic data insights to better inform clinical trials and drug development'.

AstraZeneca will also partner with the Wellcome Trust Sanger Institute's Genome Centre in Cambridge to identify new drug targets, as well as the Institute for Molecular Medicine in Helsinki, Finland, to study rare genetic variants among the Finnish population using records in their national biobank.

At the press conference announcing the collaboration, Dr Mike Stratton, the Sanger Institute's director, said that the institute's scientists would 'walk the corridors of AstraZeneca' and 'open the doors between the two intellectual worlds', according to Science

No financial details of the deals have been disclosed.

SOURCES & REFERENCES
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
26 September 2016 - by Ayala Ochert 
China has opened a national gene bank that could ultimately be the world's biggest, eventually housing 300 million genetic samples...
20 June 2016 - by Rikita Patel 
Genomics could help predict drug side effects in patients with type 2 diabetes early in the drug development process, according to a study...
13 June 2016 - by Kulraj Singh Bhangra 
The US National Institutes of Health has announced a new initiative that encourages the sharing of genomic and clinical data among researchers across the world...
30 March 2015 - by Kirsty Oswald 
Genomics England has announced a new consortium that will see it share data from the 100,000 Genomes Project with major industry players...
2 February 2015 - by Claire Downes 
AstraZeneca has joined up with academic and industrial research partners to use CRISPR, a new and much-hyped gene-editing technology in their quest for new medicines....
26 August 2014 - by Dr Molly Godfrey 
The DNA sequencing company Illumina have announced collaborations with three major pharmaceutical companies - AstraZeneca, Sanofi and Johnson & Johnson - to develop a single test for several gene mutations in cancer...
28 November 2011 - by Dr Rosie Gilchrist 
An initiative has been launched to collect genetic data from NHS cancer patients in the hope of developing new, personalised treatments....
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.